| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
1 Department of Pathology, S.H. Ho Foundation Research Laboratories and Jockey Club Clinical Research Centre, and 2 Department of Biochemistry, Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong
Requests for reprints: Irene O.L. Ng, Department of Pathology, University of Hong Kong, Queen Mary Hospital, Room 127B, University Pathology Building, Pokfulam, Hong Kong. Phone: 852-2855-4197; Fax: 852-2872-5197; E-mail: iolng{at}hku.hk.
Deleted in liver cancer (DLC1) is a candidate tumor suppressor gene recently isolated from human hepatocellular carcinoma. Structurally, DLC1 protein contains a conserved GTPase-activating protein for Rho family protein (RhoGAP) domain, which has been thought to regulate the activity of Rho family proteins. Previous studies indicated that DLC1 was frequently inactivated in cancer cells. In the present study, we aimed to characterize the tumor suppressor roles of DLC1 in hepatocellular carcinoma. We showed that DLC1 significantly inhibited cell proliferation, anchorage-independent growth, and in vivo tumorigenicity when stably expressed in hepatocellular carcinoma cells. Moreover, DLC1 expression greatly reduced the motility and invasiveness of hepatocellular carcinoma cells. With RhoGAP-deficient DLC1 mutant (DLC1-K714E), we showed that the RhoGAP activity was essential for DLC1-mediated tumor suppressor function. Furthermore, the 292– to 648–amino acid region and the steroidogenic acute regulatory related lipid transfer domain played an auxiliary role to RhoGAP and tumor suppressor function of DLC1. Taken together, our findings showed that DLC1 functions as a tumor suppressor in hepatocellular carcinoma and provide the first evidence to support the hypothesis that DLC1 suppresses cancer cell growth by negatively regulating the activity of Rho proteins.
This article has been cited by other articles:
|
|
 |
|
  A. Lahoz and A. Hall DLC1: a significant GAP in the cancer genome Genes & Dev., July 1, 2008; 22(13): 1724 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Xue, A. Krasnitz, R. Lucito, R. Sordella, L. VanAelst, C. Cordon-Cardo, S. Singer, F. Kuehnel, M. Wigler, S. Powers, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma Genes & Dev., June 1, 2008; 22(11): 1439 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Qian, G. Li, H. K. Asmussen, L. Asnaghi, W. C. Vass, R. Braverman, K. M. Yamada, N. C. Popescu, A. G. Papageorge, and D. R. Lowy Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities PNAS, May 22, 2007; 104(21): 9012 - 9017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Shang, S. Y. Moon, and Y. Zheng p200 RhoGAP Promotes Cell Proliferation by Mediating Cross-talk between Ras and Rho Signaling Pathways J. Biol. Chem., March 23, 2007; 282(12): 8801 - 8811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. Liao, L. Si, R. W. deVere White, and S. H. Lo The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1 J. Cell Biol., January 1, 2007; 176(1): 43 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. P. Yam, F. C. F. Ko, C.-Y. Chan, D.-Y. Jin, and I. O.-L. Ng Interaction of Deleted in Liver Cancer 1 with Tensin2 in Caveolae and Implications in Tumor Suppression. Cancer Res., September 1, 2006; 66(17): 8367 - 8372. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
